Group 1 - The article discusses the competitive landscape between Novo Nordisk and Eli Lilly as they enter a new phase in their long-standing rivalry, particularly focusing on the GLP-1 oral medication market [1] - The analysis emphasizes the importance of a fundamentals-first approach in investment decisions, despite the influence of market sentiment and algorithm-driven trading [1] Group 2 - The author has a background in Economics and has been managing investments since 1999, gaining insights across various market cycles [1] - The article does not provide any specific investment recommendations or positions in the companies mentioned, indicating an objective analysis [2][3]

Core Insights - Eli Lilly has emerged as a significant growth player in the pharmaceutical industry, particularly due to its leadership in the weight-loss drug market, delivering double-digit revenue growth [5][2] - The company's weight loss portfolio generated over $10 billion in revenue in the latest quarter, highlighting its strong market position [5][6] - Analysts predict that the weight loss drug market could approach $100 billion by the end of the decade, positioning Eli Lilly to benefit significantly from this growth [8] Company Overview - Eli Lilly's key products include tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, which have been prescribed for weight loss since 2022 [6][5] - The company has a market capitalization of $1.0 trillion and a gross margin of 83.03%, indicating strong financial health [7] - Demand for Lilly's drugs has been high, often surpassing supply, and the company is actively expanding its weight loss portfolio with new candidates like orforglipron and retatrutide [7][6] Market Potential - The weight loss drug market is expected to grow significantly, with analysts forecasting it to reach nearly $100 billion by the end of the decade, which presents a substantial opportunity for Eli Lilly [8] - The company's strategic focus on expanding its product offerings in this lucrative market could enhance its growth trajectory and revenue potential [7][8] Investment Strategy - Including Eli Lilly in a diversified portfolio of quality stocks is suggested as a strategy to potentially achieve significant retirement savings, with the company being a strong candidate for long-term investment [9]

SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (”Lilly”).ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various mod ...

本届服贸会还将广泛邀请各方设展办会、洽商合作，继续设置主宾国、主宾省，邀请国际组织、服务贸 易强国和地区、行业龙头企业等设展办会；邀请境外国家和地区、省区市、国际组织及领军企业发布、 解读招商引资政策，推介产业优势。 本报讯（记者马婧）记者今天从2026年中国国际服务贸易交易会媒体吹风会获悉，2026年服贸会将于 2026年9月9日至13日举办。目前，已有挪威、斯洛伐克、世界知识产权组织、世界贸易中心协会等10余 个国家和国际组织，已计划继续设展办会；港澳台地区计划继续设立展台；阿斯利康、礼来、西门子、 中远海运等近百家世界500强和行业龙头企业意向参展。 中国国际服务贸易交易会已成功举办12届，累计吸引近200个国家和地区的147万展客商参与。2025年 起，服贸会固定于每年9月第二周的星期三到星期日在首钢园举办，会期5天。2026年服贸会将于9月9日 至13日举办，地点仍在首钢园。首钢园也正在为打造服贸会永久会址进行升级改造，9月将旧貌换新 颜，迎接四方宾客。融合展览、会议、洽谈与文化活动功能为一体的多功能特色"会展小镇"将与大家见 面。 2026年服贸会计划继续高规格举办全球服务贸易峰会，邀请外国政要、 ...

本文源自：金融界AI电报 礼来公司将向ABL Bio支付4000万美元用于许可、研究及合作，并进行1500万美元股权投资。ABL Bio 与礼来公司合作开展基于双特异性抗体平台"Grabody"的联合研究。 ...

Core Insights - Eli Lilly has achieved strong returns due to its advancements in weight management, positioning itself as a leader in this market [1] - The company is not resting on its laurels and continues to innovate, suggesting it may outpace competitors [1] Competitive Landscape - Novo Nordisk is the only significant competitor to Eli Lilly in the weight loss drug market, with its product Wegovy generating billions in sales [2] - Novo Nordisk is seeking label expansions and has requested FDA approval for a higher dose of semaglutide, the active ingredient in Wegovy [3][4] Product Performance - Eli Lilly's Zepbound has demonstrated superior average weight loss compared to Wegovy in clinical trials, generating $9.3 billion in revenue in the first nine months of 2025, while Wegovy generated approximately $9 billion [5] - Novo Nordisk's pipeline includes Amycretin, which is in phase 3 studies, but Eli Lilly's pipeline remains stronger with promising candidates like orforglipron and retatrutide [6][7] Market Position - Eli Lilly is clearly leading the weight loss market, with its current and future products positioning it ahead of competitors [8] - Novo Nordisk's CagriSema, which achieved a mean weight loss of 22.7%, is under regulatory review but still falls short compared to Eli Lilly's offerings [9]

U.S. financial markets are observing a full closure today, Thursday, December 25, 2025, in celebration of the Christmas holiday. Trading on both the New York Stock Exchange (NYSE) and Nasdaq is suspended for the entire day, with normal operations set to resume on Friday, December 26, 2025. This pause follows a shortened, yet record-setting, trading session on Christmas Eve, Wednesday, December 24, where major indexes continued their upward trajectory, fueling hopes of a "Santa Claus rally" to close out the ...

近日，礼来公司旗下创新药替尔泊肽被正式纳入新版国家医保目录，带动国内降糖与减重药物市场迎来 新一轮降价。经实测，在替尔泊肽医保价落地前，部分线上医药平台已率先启动降价预售活动。美团买 药显示，替尔泊肽10mg规格预售到手价低至450元，相当于此前价格的2折左右。同时，司美格鲁肽等 其他GLP-1药物线上价格也出现不同程度调整，医保政策对院外市场价格的传导效应逐步显现。 （文章来源：第一财经） ...

新晋"全球药王"替尔泊肽，在2025年医保新药目录谈判后，价格即将大幅下降。 文 ｜ 胡香赟 编辑 ｜ 海若镜 封面来源 ｜ IC Photo 近期结束的国家医保目录调整中，多款GLP-1产品被纳入，其中就包括礼来的替尔泊肽，用于成人2型糖尿病治疗。 截至目前，国家医保局并未公布谈判价格结果。但在多位内分泌科、代谢科医生的社交媒体中，流传出2026年1月1日后替尔泊肽将执行的新价格，同比大幅 下降。不同用量的月费价格（每月4次）分别为：324.1元（2.5mg)、551元(5mg）、751.6元（7.5mg）和936.7元（10mg）。 网传替尔泊肽2026年即将执行的院内新价格 36氪就该价格向礼来方面求证，礼来未予置评，并表示以"医保局官方发布为准"。 另两家开发GLP-1新药的药企人士称，这组替尔泊肽价格数据与其了解的区间接近，"确实降了很多"。 此外，36氪注意到，多个主流电商平台，均已推出替尔泊肽新的预售价格，降幅显著。例如2.5mg*4次剂量的月费在450元-600元不等，较国谈前低了六、七 成。一家医药电商平台直接打出了"医保国谈降价、惠及更多患者"的标语。 2025年前三季度，替尔泊肽的全球销 ...

Core Viewpoint - Novo Nordisk has received FDA approval for its oral weight loss drug Wegovy, set to launch in January 2026 at a starting price of $149 per month, potentially making it more accessible than its injectable counterpart [5][14]. Group 1: Novo Nordisk's Product Launch - The oral version of Wegovy is designed to provide weight loss results comparable to the injectable version, with the added convenience of daily oral administration [5]. - The active ingredient in the oral drug is semaglutide, the same as in the injectable Wegovy and Ozempic, but with a higher dosage in the new formulation [5]. - Novo Nordisk has reached an agreement with Trump to allow self-paying patients to purchase the drug at the same price through a new website launching in January [5]. Group 2: Competitive Landscape - Eli Lilly, a major competitor, is also developing an oral weight loss drug and has submitted it for FDA approval, which is expected to follow shortly after Novo Nordisk's approval [7]. - Eli Lilly's injectable weight loss drugs use tirzepatide, while its oral formulation is based on a new ingredient, orforglipron [7]. - Recent performance shows Eli Lilly's Zepbound has surpassed Novo Nordisk's Wegovy in revenue contribution [8]. Group 3: Drug Efficacy and Development - Novo Nordisk's oral drug includes a protective component, SNAC, to prevent rapid degradation in the stomach, requiring patients to take it on an empty stomach [11]. - Clinical studies indicate that Novo Nordisk's oral formulation achieves weight loss comparable to its injectable version over 64 weeks, while Eli Lilly's oral drug shows less efficacy compared to its injectable [11]. - Both companies are exploring next-generation drugs, with Novo Nordisk researching cagrilintide and Eli Lilly focusing on retatrutide, which may offer enhanced weight loss and metabolic benefits [12]. Group 4: Market Impact and Stock Performance - Following the approval of the oral weight loss drug, Novo Nordisk's stock rose by 7.30%, reaching a market capitalization of $175 billion, although it has seen a year-to-date decline of 38.35% [14]. - Eli Lilly's stock has increased by 39.54% year-to-date, reflecting strong market confidence in its weight loss products [14]. - Pfizer has entered the weight loss drug market by acquiring Metsera for approximately $100 billion, aiming to develop a monthly injectable GLP-1 receptor agonist [13][14].